Results 121 to 130 of about 508,488 (299)
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Increased brain coverage and efficiency when measuring current-induced magnetic fields by use of simultaneous multi-slice echo-planar MRI. [PDF]
PLoS OneCunha T +3 more
europepmc +1 more source
VALUING THE IMPACT OF SYNERGIES ON PUBLIC MERGERS/ACQUSITIONS IN THE PHARMACEUTICAL SECTOR ON THE EUROPEAN CAPITAL MARKETS [PDF]
Valuing and identifying synergies in mergers and acquisitions is one of the important issues in Corporate Finance. The aim of this paper is to value the impact of synergies resulted from mergers/acquisitions in the European pharmaceutical sector ...
Oana Resceanu
core
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Macroeconomic Conditions and Business Exit: Determinants of Failures and Acquisitions of UK Firms [PDF]
We study the impact of macroeconomic instability on business exit in a world where acquisition and bankruptcy are co-determined. Our objective is to discover how the processes that determine bankruptcies and acquisitions depend on the macroeconomic ...
Arnab Bhattacharjee +3 more
core
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
CEO Preferences and Acquisitions [PDF]
This paper explores the impact of target CEOs’ retirement preferences on the incidence, the pricing, and the outcomes of takeover bids. Mergers frequently force target CEOs to retire early, and CEOs’ private merger costs are the forgone benefits of ...
Dirk Jenter, Katharina Lewellen
core
Acquisitions: Drawings for Objects
The Rijksmuseum Bulletin, 2016 van der Hoorn, Esther, Baarsen, Reinier
openaire +4 more sources